European Pharmaceutical Review

JANUARY 10, 2024

A lymph node-targeted cancer vaccine has shown potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers in patients who have had surgery, according to a Phase I trial led by US researchers. Patients were given no more than 10 doses of the ELI-002 cancer vaccine targeted toward KRAS G12D and G12R mutations. “It

Vaccines 83

Vaccines Chemotherapy 83

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

SEPTEMBER 21, 2022

As a spokesperson for the PM Society commented, “We were very cognisant and respectful of events unfolding beyond the awards, but after much consideration and speaking with attendees, we decided to go ahead and we’re so glad that we did. The post 13th PM Society Digital Awards – celebrating creative innovation appeared first on.

Communication 54

Communication Vaccines 54

STAT

MARCH 5, 2024

After 18 months of debate, the World Trade Organization failed to adopt a controversial proposal to waive intellectual property protection for Covid-19 diagnostics and treatments, ending a furious attempt by civil society groups to bolster global access to needed medical products. The failure was not a surprise.

Pharmaceutical Manufacturing 234

Pharmaceutical Manufacturing Vaccines 234

Pharmaceutical Technology

JULY 15, 2022

The Brazilian Health Regulatory Agency (Anvisa) has granted emergency use authorization for Sinovac Biotech’s Covid-19 vaccine, CoronaVac, in children aged three to five years. Subjects in this age group can receive the same vaccine dosage authorised in patients aged six to 17 years, as well as adults.

Vaccines 64

Vaccines Dosage Immunity Immunization 64

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 92

Vaccines Immunity Immunization 92

Pharmafile

JANUARY 13, 2023

The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known severe “adverse events of special interest” (AESIs) which appeared in post-vaccination studies. read more. read more.

Vaccines 78

Vaccines Communication 78

pharmaphorum

JANUARY 11, 2022

What HCPs think about mandatory vaccination. The practice of making vaccinations mandatory within a population has always been controversial. Historically, the first example of this was during the smallpox epidemic in the 1800s , when some European countries attempted to make vaccination against the disease compulsory.

Vaccines 80

Vaccines Immunity Immunization Hospitals 80

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. The post Positive results for mRNA vaccine in melanoma patients appeared first on European Pharmaceutical Review.

Vaccines 93

Vaccines Research Laboratories Immunity Immunization 93

The Guardian - Pharmaceutical Industry

JANUARY 16, 2024

Darius Hughes was a key figure in Pfizer’s pioneering Covid vaccine drive.

Vaccines 128

Vaccines 128

pharmaphorum

JANUARY 15, 2021

Now, speaking to him as the first vaccines are deployed in the UK, he highlights the importance of GSK’s employees and culture to the future of the company post-COVID. He highlights GSK’s recently announced sustainability ambitions as an example of how the company is aiming to “do the right thing” for wider society.

Vaccines 101

Vaccines Drug Development 101

The Guardian - Pharmaceutical Industry

APRIL 7, 2023

Exclusive: Pharmaceutical firm says groundbreaking jabs could save millions of lives ‘A silver lining’: how Covid ushered in a vaccines golden era Millions of lives could be saved by a groundbreaking set of new vaccines for a range of conditions including cancer, experts have said.

Vaccines 108

Vaccines 108

The Guardian - Pharmaceutical Industry

AUGUST 19, 2022

Unlike jabs, nasal vaccines target the respiratory tract, the body’s first line of defence against infection People who receive a Covid booster dose in the UK next month will be among the first in the world to receive Moderna’s dual-variant vaccine , which protects against two strains of the virus.

Vaccines 98

Vaccines Immunity Immunization 98

The Guardian - Pharmaceutical Industry

DECEMBER 12, 2023

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid-19 pandemic.

Vaccines 54

Vaccines Immunity Immunization 54

pharmaphorum

OCTOBER 5, 2020

As European regulators begin a rolling review of AstraZeneca’s COVID-19 vaccine, the focus in the UK has shifted to the government’s plans to distribute any vaccine that is deemed to be a safe and effective way of preventing the disease. There is going to be no vaccination of people under 18.

Vaccines 108

Vaccines 108

pharmaphorum

OCTOBER 8, 2021

This impact on individuals has then extended to broader society with the wider economic costs of mental illness in England estimated at £105.2 We all know that prevention is better than cure – and a strong example is widespread COVID-19 vaccination, which is proving to be one of the most effective tools in helping us return to everyday life.

Vaccines 52

Vaccines 52

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 71

Vaccines Pharmaceutical Companies Pharmaceutical Companies Drug Development 71

Pharmaceutical Technology

MAY 1, 2023

After a long period of inactivity in RSV vaccine development , two pharmaceutical companies are now approaching regulatory decisions for their RSV vaccines. Both Pfizer and GSK have major approval decisions regarding the use of their RSV vaccines for older adults this May. What incentivises a country to cover a vaccine?

Vaccines 52

Vaccines Nursing Homes Communication Pharmaceutical Companies 52

The Guardian - Pharmaceutical Industry

OCTOBER 10, 2022

Scientists ditch plans to develop nasal spray version of Oxford/AstraZeneca vaccine in its current form Hopes of distributing the Oxford/AstraZeneca Covid vaccine as a nasal spray have been dealt a blow after researchers said it performed poorly in its first clinical trial. Continue reading.

Vaccines 83

Vaccines 83

STAT

JUNE 7, 2023

Now that the biggest meeting in cancer research — and, really, one of the biggest annual conferences for the pharmaceutical industry as a whole — has drawn to a close, what did we learn from the latest annual meeting of the American Society of Clinical Oncology,   STAT asks. Here

Hospitals 162

Hospitals Vaccines 162

pharmaphorum

MARCH 16, 2021

The decision by around a dozen EU countries to suspend dosing with AstraZeneca’s COVID-19 vaccine is facing criticism, amid fears that it could undermine the response to the pandemic in Europe. . It is a completely one-sided argument, statistically, that we need to be vaccinating,” he said. “I

Vaccines 88

Vaccines Adverse Reactions 88

pharmaphorum

JANUARY 13, 2021

IO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) to further develop its cancer vaccine technology that has boosted efficacy of PD-1 immunotherapy in early trials. The post IO Biotech raises $155m to develop breakthrough cancer vaccine appeared first on.

Vaccines 67

Vaccines Immunity Immunization Compounding 67

pharmaphorum

OCTOBER 23, 2020

Is a century-old vaccine a ‘game-changer’ for COVID-19? Today, the notion of ‘data science’ has permeated almost every area of society. This is especially true in the search for effective therapies to fight COVID-19, and a vaccine. Understanding the link between COVID-19 and the BCG vaccine.

Vaccines 83

Vaccines Immunity Immunization Hospitals 83

pharmaphorum

OCTOBER 21, 2022

The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. The emergence of COVID-19 meant that public awareness around vaccination and its importance in fighting the spread of infectious disease has increased rapidly.

Vaccines 95

Vaccines Immunity Immunization Compounding 95

Eye on FDA

SEPTEMBER 10, 2020

Vaccines for COVID-19 are the focus of the moment – politically and scientifically speaking. Scientifically, there was the big news that a vaccine trial had experienced a serious adverse event bringing a pause to bear in its continuation, likely throwing further cold water on the political side of the equation.

Communication 82

Communication Vaccines Immunity Immunization 82

Express Pharma

DECEMBER 13, 2023

The FOGSI Run for Gender Equality is specifically organised to spread awareness on Anemia and Rh negative pregnancies among women across the country Bharat Serums and Vaccines Limited (BSV) along with Federation of Obstetric and Gynecological Societies of India (FOGSI) organised the FOGSI Run for Gender Equality (the Run) at Airoli, Navi Mumbai.

Vaccines 101

Vaccines 101

pharmaphorum

JANUARY 8, 2021

As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford/AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.

Vaccines 57

Vaccines Immunity Immunization Medical Schools 57

Putting Patients First Blog

JANUARY 25, 2024

Recognizing Every Day as Women’s Health Research Day  January 25, 2024 By: Kathryn Schubert, CEO and President, Society for Women’s Health Research January 25 marks Women’s Health Research Day , the anniversary of the implementation of the National Institutes of Health (NIH) Policy on Sex as a Biological Variable (SABV) in 2016.

Vaccines 85

Vaccines Hospitals 85

pharmaphorum

JANUARY 8, 2021

As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.

Vaccines 52

Vaccines Immunity Immunization Medical Schools 52

pharmaphorum

FEBRUARY 15, 2021

Newly developed vaccines will be supplied by the World Health Organization in a bid to contain the pandemic, officials said. That outbreak mainly affected Guinea and its neighbours Liberia and Sierra Leone and several vaccines have since been trialled and successfully used to fight the disease in the Democratic Republic of Congo.

Vaccines 98

Vaccines 98

pharmaphorum

DECEMBER 1, 2020

GPs in the UK have been urged to encourage patients to self-care, in advance of the anticipated roll-out of COVID-19 vaccines and the extra workload this will create. The post UK patients urged to self-care ahead of vaccine roll-out appeared first on.

Vaccines 62

Vaccines 62

European Pharmaceutical Review

SEPTEMBER 1, 2023

At the end of August 2023, BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) had recommended its adapted Comirnaty mRNA-based vaccine for regulatory approval as preventive treatment against the COVID-19 Omicron XBB.1.5 subvariant. percent of the total mRNA therapy market by 2029.

Immunity 86

Immunity Immunization Vaccines 86

European Pharmaceutical Review

APRIL 5, 2024

Study data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Last week, Moderna shared promising data for its next-generation COVID-19 vaccine. As of the latest data cut off at the end of May 2023, over 15 person-years of the therapy were administered.

Vaccines 85

Vaccines 85

European Pharmaceutical Review

AUGUST 18, 2022

Merck (MSD outside of the US and Canada) has entered into a collaboration agreement with Orna Therapeutics to discover, develop and commercialise multiple programmes of engineered circular RNA (oRNA) therapies, including vaccines and therapeutics in the areas of infectious disease and oncology.

Vaccines 84

Vaccines Research Laboratories Packaging 84

pharmaphorum

MARCH 15, 2022

The COVID-19 pandemic has radically disrupted traditional medical society conferences in a way that could scarcely have been imagined in 2019. The vast majority of societies were able to transition their planned physical events to virtual formats within remarkably short periods of time, and some delivered impressive attendee experiences.

Labelling 93

Labelling Vaccines Communication 93

pharmaphorum

MARCH 3, 2021

T-cell therapies for COVID-19 were discussed at the American Society of Haematology (ASH) conference late last year, where AlloVir provided proof-of-concept data for its off-the-shelf T cell therapy that specifically targets the virus. The post ISA plans trials of T-cell boosting COVID-19 therapy appeared first on.

Immunity 81

Immunity Immunization Vaccines Hospitals 81

pharmaphorum

JANUARY 31, 2022

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 that focuses on its use as a booster dose. The Japanese group says it hopes to complete clinical development of the vaccine and bring it to market in Japan before the end of the year.

Vaccines 69

Vaccines Pharmaceutical Companies Pharmaceutical Companies Hospitals 69